3D rendering of a checkpoint inhibitor binding PD-1, a protein on the surface of an immune T cell. This article is part of an ongoing series on checkpoint inhibitors, a novel cancer immunotherapy.

Characterization of TP53 mutations in actionable driver-negative non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...

A woman receiving an IV at the hospital. This article is part of an ongoing series on novel cancer advances, including immunotherapies such as CAR T therapy and checkpoint inhibitors. Future ...

Immune checkpoint molecules play a crucial role in keeping the immune system in balance and preventing an attack on the ...

Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, ...

Epithelioma Treatment Market to reach USD 13.1 billion by 2035, driven by rising skin cancer cases and growing adoption of ...